Sandra Rocha

Sandra Rocha

Auto-generated profile, based on publicly available information

Sandra Rocha

Department of Biology and Biological Engineering, Chalmers University of Technology, 412 96 Gothenburg, Sweden

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 June 2020 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
PDF file
JHJonas K. Hannestad
Jonas K. Hannestad
SRSandra Rocha
Sandra Rocha
BABjörn Agnarsson
Björn Agnarsson
VZVladimir P Zhdanov
Vladimir P Zhdanov
PWPernilla Wittung-Stafshede
Pernilla Wittung-Stafshede
FHFredrik Höök
Fredrik Höök
Significance: Neurodegenerative diseases are increasing among the world's population, but there are no cures. These disorders all involve proteins that assemble into amyloid fibers which results in brain cell death. Evidence suggests that association of these proteins with lipid membranes is crucial for both functional and pathological roles. In Parkinson's disease, the involved protein, α-synuclein, is thought to function in trafficking of lipid vesicles in the brain. In search of mechanistic origins, increasing focus is put on identifying neurotoxic reactions induced by membrane interactions. To contribute new clues to this question, we here employed a new surface-sensitive scattering microscopy technique. With this approach, we discovered that α-synuclein perturbs vesicles in a stepwise and lipid-dependent fashion already at very low protein coverage.

1 October 2015 in Colloids and Surfaces B: Biointerfaces
Verified
Journal Article
Closed access
Joana LoureiroJoana Loureiro
Joana Loureiro
BGBárbara Gomes
Bárbara Gomes
Gert FrickerGert Fricker
Gert Fricker
ICIsabel Cardoso
Isabel Cardoso
CRCarlos A Ribeiro
Carlos A Ribeiro
SRSandra Rocha
Sandra Rocha

14 March 2014 in Journal of Materials Chemistry B
Verified
Journal Article
Open access
PDF file
Joana LoureiroJoana Loureiro
Joana Loureiro
RCRosa Crespo
Rosa Crespo
HBHans Börner
Hans Börner
PMP. M. Martins
P. M. Martins
FRFernando Rocha
Fernando Rocha
SRSandra Rocha
Sandra Rocha
The aggregation of amyloid-β peptide (Aβ) has been linked to the formation of neuritic plaques, which are pathological hallmarks of Alzheimer's disease. We synthesized peptides containing fluorinated amino acids and studied their effect on the Aβ aggregation. The peptides were based on the sequence LVFFD, in which valine was substituted by either 4,4,4-trifluorovaline or 4-fluoroproline, or the phenylalanine at position 3 was replaced by 3,4,5-trifluorophenylalanine. Our results demonstrate that fluorination of the hydrophobic residue valine or phenylalanine is effective in preventing the Aβ aggregation. This study opens up the possibility of using new sequences based on fluorinated amino acids to inhibit the amyloid-fibril formation.

1 September 2013 in Current Pharmaceutical Design
Verified
Journal Article
Closed access
SRSandra Rocha
Sandra Rocha
The discovery of drugs for Alzheimer's disease (AD) therapy that can also permeate the blood brain barrier (BBB) is very difficult owing to its specificity and restrictive nature. The BBB disruption or the administration of the drug directly into the brain is not an option due to toxic effects and low diffusion of the therapeutic molecule in the brain parenchyma. A promising approach for drug systemic delivery to the central nervous system is the use of nanosized carriers. The therapeutic potential of certain nanopharmaceuticals for AD has already been demonstrated in vivo after systemic delivery. They are based on i) conjugates of drug and monoclonal antibodies against BBB endogenous receptors; ii) cationized or end terminal protected proteins/peptides; iii) liposomes and polymeric nanoparticles coated with polysorbate 80, cationic macromolecules or antibodies against BBB receptors/amyloid beta-peptides. Optimization and further validation of these systems are needed.

10 September 2015 in Future Science OA
Verified
Journal Article
Open access
Joana LoureiroJoana Loureiro
Joana Loureiro
BGBárbara Gomes
Bárbara Gomes
MCManuel A.N. Coelho
Manuel A.N. Coelho
Maria de Lourdes PereiraMaria de Lourdes Pereira
Maria de Lourdes Pereira
SRSandra Rocha
Sandra Rocha
Aim: The present study was designed to test the cellular uptake of PEGylated liposomes targeted to transferrin receptor and to α-synuclein by a cell model of the blood–brain barrier (BBB). Materials & methods: PEGylated immunoliposomes were prepared with anti-transferrin receptor OX26 and anti-α-synuclein LB509 antibodies to overcome the BBB in Parkinson's disease. Results: The doubly targeted immunoliposomes bind to transferrin receptor and to α-synuclein protein, as assessed by ELISA assays. We establish that 40% of an encapsulated tested drug (epigallocatechin-3-gallate) is released in a time frame of 44 h, which is reasonable for sustained release. The cellular uptake of doubly targeted immunoliposomes in cultured brain endothelial cells hCMEC/D3 was two-times more efficient than that of PEGylated liposomes. Conclusion: Immunoliposomes targeted to BBB receptors and to α-synuclein could potentially enable the transport of drugs across the BBB and reach one of the drug targets in Parkinson's disease. Lay The blood–brain barrier (BBB) prevents the distribution of drugs into the brain, making the development of new treatments for brain disorders such as Parkinson's disease difficult. This is due to the presence of tight cell–cell junctions within the brain capillary endothelium. Nanocarriers that transport drugs across the BBB enable noninvasive modes of drug delivery (e.g., oral, systemic routes) to the brain. In the present study, we developed vesicles targeted with antibodies to BBB receptors and to a biological target of Parkinson's disease. This technology, known as Trojan horse technology, uses endogenous molecules that are able to cross the BBB through receptors present in the brain capillary endothelium.

6 February 2017 in Quarterly Reviews of Biophysics
Verified
Journal Article
Open access
PDF file
JKJuris Kiskis
Juris Kiskis
IHIstvan Horvath
Istvan Horvath
PWPernilla Wittung-Stafshede
Pernilla Wittung-Stafshede
SRSandra Rocha
Sandra Rocha
Amyloid formation of the synaptic brain protein α-synuclein (αS) is related to degeneration of dopaminergic neurons in Parkinson's disease patients. αS is thought to function in vesicle transport and fusion and it binds strongly to negatively charged vesicles in vitro. Here we combined circular dichroism, fluorescence and imaging methods in vitro to characterize the interaction of αS with negatively charged vesicles of DOPS (1,2-dioleoyl-sn-glycero-3-phospho-L-serine, sodium salt) and DOPG (1,2-dioleoyl-sn-glycero-3-phospho-(1′-rac-glycerol), sodium salt) and the consequences of such interactions on αS amyloid formation. We found that lipid head-group chemistry modulates αS interactions and also affects amyloid fiber formation. During the course of the experiments, we made the unexpected discovery that pre-formed αS oligomers, typically present in a small amount in the αS starting material, acted as templates for linear growth of anomalous amyloid fibers in the presence of vesicles. At the same time, the remaining αS monomers were restricted from vesicle-mediated nucleation of amyloid fibers. Although not a dominant process in bulk experiments, this hidden αS aggregation pathway may be of importance in vivo.